Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

101.00 +1.82 (+1.84%)
Streaming Delayed Price Updated: 9:49 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
96 97 Next >
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
From Merck & Co., Inc.
Via Business Wire
3 Sectors That Could Get Slammed by Attempts to Reduce U.S. Debt
With Washington likely having to take steps to cut the U.S. deficit within the next few years, here are three sectors at risk. 
Via InvestorPlace
7 Quiet Blue-Chip Stocks on the Verge of a Big Breakout Rally
These are the undervalued blue-chip stocks to buy as they represent companies with a steady growth and robust cash flow outlook. 
Via InvestorPlace
A Closer Look at Merck & Co's Options Market Dynamics
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Merck & Co
Via Benzinga
What's Going On With Merck Stock On Friday?
The CDC's Advisory Committee on Immunization Practices recommends Merck's Capvaxive for adults 65+ and certain at-risk individuals 19-64. Merck also announces CHMP's positive recommendation for... 
Via Benzinga
Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)
From Merck & Co., Inc
Via Business Wire
CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults
From Merck & Co., Inc.
Via Business Wire
Competitor Analysis: Evaluating Merck &amp; Co And Competitors In Pharmaceuticals Industry
Via Benzinga
Dow Jones Powerhouse Merck Dives On Surprise FDA Rejection
The FDA rejected Merck's Daiichi Sankyo-partnered antibody drug conjugate. 
Via Investor's Business Daily
Topics Stocks
Exposures Product Safety US Equities
This Recent FDA Approval Is Bad News for Pfizer
One of the pharma giant's top-selling products is about to face some intense competition. 
Via The Motley Fool
Exposures Product Safety
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
The FDA issued a Complete Response Letter for Daiichi Sankyo and Merck's BLA for patritumab deruxtecan targeting EGFR-mutated NSCLC due to third-party manufacturing facility inspection findings. The... 
Via Benzinga
Exposures Product Safety
These Are The Best Dow Jones Stocks Of 2024 Thus Far
The AI boom helped to produce two best Dow Jones stocks, including newbie Amazon. 
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
From Daiichi Sankyo
Via Business Wire
Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight
On Tuesday, Merck Group revealed an unexpected decision to end a Phase III trial of its cancer drug Xevinapant. This move threatens to undermine confidence the research abilities of the Darmstadt,... 
Via Benzinga
7 Dividend Stocks to Buy Now for Enhanced Returns
These dividend stocks can round out a diversified portfolio - or anchor a value-based income investment strategy. 
Via InvestorPlace
USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza
From Merck & Co., Inc.
Via Business Wire
Analyst Sees Keros Therapeutics As Next Acceleron, Set For Major Biotech Growth
Keros Therapeutics is advancing novel therapies for hematological and cardiopulmonary disorders via TGF-β signaling regulation. Oppenheimer rates KROS Outperform with a $102 price target. 
Via Benzinga
Gossamer Bio's Clean Safety Profile Differentiates It From Merck, Analyst Says
Oppenheimer initiated coverage on Gossamer Bio, highlighting seralutinib's clean long-term safety profile for pulmonary arterial hypertension. Seralutinib shows potential in underserved markets. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Forget Nvidia: Prominent Billionaires Are Selling It in Favor of These 7 Top-Notch Stocks
More than a half-dozen of Wall Street's most-successful billionaire investors dumped shares of Nvidia during the March-ended quarter and made these seven stocks their top buys. 
Via The Motley Fool
3 Undervalued Pharma Stocks to Buy for Dividends and Capital Gains
These are the undervalued pharma stocks and represent companies with a deep research pipeline, that provides sustained growth visibility. 
Via InvestorPlace
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And More
Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach. 
Via Benzinga
AbbVie Inc. Dividend Stock Analysis - Saturday, June 22
Here are some highlights from a detailed, quantitative analysis AbbVie Inc. stock. Let's take a closer look at various factors, such as the stock's value and dividend. 
Via Talk Markets
Gilead Sciences Faces Wall Street Speculation About Obesity Drugs Despite Focus On Liver Treatments
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatments. 
Via Benzinga
3 Top Penny Stocks to Skyrocket Your Wealth in 2024
Find out about the top penny stocks to buy this year for a chance to see incredible results down the road as they soar to new heights. 
Via InvestorPlace
Covid-19 Pharma Stars Continue Their Quest To Set New Standards In Cancer Treatment
AstraZeneca PLC (NASDAQ: AZN) kicked off the week by receiving approval from the U.S. Food and Drug Administration for its blockbuster cancer drug Imfinzi combined with chemotherapy being used as a... 
Via Benzinga
Exposures COVID-19
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Exposures Death
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
From FN Media Group LLC
Via GlobeNewswire
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
96 97 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.